Polpharma Biologics announced on July 15th 2022 that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorisation Application (MAA) for biosimilar natalizumab, a proposed biosimilar to Tysabri®. In the European Union, Tysabri is approved to treat adults with relapsing-remitting MS (RRMS) who have highly active disease. It is approved for adults with relapsing…
Upstaza™ – First disease-modifying treatment for AADC deficiency
PTC Therapeutics to launch first gene therapy directly administered into the brain PTC Therapeutics, Inc. announced on July 20th, 2022 that Upstaza™ (eladocagene exuparvovec) was granted marketing authorisation by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into…
National Acquired Brain Injury Strategy
Fact finding tour to help shape Acquired Brain Injury strategy Chris Bryant MP has visited three very different facilities offering neurorehabilitation services across the country to gather information for the new Government wide Acquired Brain Injury (ABI) Strategy. Chris Bryant is the Chair of the All Party Parliamentary Group for ABI and the Co-Chair of…
Man feeds himself with robotic arms
Robotic arms connected directly to brain of partially paralysed man allows him to feed himself. Recent advances in neural science, robotics, and software have enabled scientists to develop a robotic system that responds to muscle movement signals from a partially paralysed person relayed through a brain-machine interface. Two robotic arms – a fork in one…
Trial shows benefits in patients with Duchenne Muscular Dystrophy
Topline Data from Phase 3 Trial shows beneficial effect of Givinostat 22nd June, 2022: Italfarmaco Group announced positive topline data from its completed Phase 3 EPIDYS trial with Givinostat, the company’s proprietary histone deacetylase (HDAC) inhibitor, in boys with Duchenne Muscular Dystrophy (DMD). The primary objective of the study was to evaluate the effects of Givinostat…
Prolonged release capsules for pain
Neuraxpharm launches Tapimio® (tapentadol) prolonged release capsules in the UK Neuraxpharm announced on June 30th 2022 the launch of Tapimio® (tapentadol) for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics. Tapimio® is the first and only prolonged release capsule formulation of tapentadol to be made available…
Preserving cognitive function in RRMS
Bristol Myers Squibb presents new data showing effect of early Zeposia (ozanimod) treatment in improving and preserving cognitive function in people with Relapsing Multiple Sclerosis. On June 24th, Bristol Myers Squibb presented results of the DAYBREAK open-label extension trial at the 8th European Academy of Neurology Congress in Vienna, Austria. New post-hoc analyses from the Zeposia (ozanimod) Phase 3…
Aubagio study: no disease activity after 2 years
More than half (58% )of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to an Italian study. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in the Journal of the Neurological Sciences. Aubagio is an oral disease-modifying therapy that has been…
Novel Early Intervention Study for Stroke Patients
MindMaze and The University of Auckland partner on novel early intervention study for stroke patients, expanding global breadth of research supporting the company’s brain tech solutions MindMaze, (digital therapeutics (DTx) for neurological recovery and care), in partnership with The University of Auckland, has announced a new interventional study that will aim to show the merits…
